Results 51 to 60 of about 820 (140)

NXT007 enhances in vitro coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formation

Research and Practice in Thrombosis and Haemostasis
Background: NXT007 is a factor (F)VIIIa-mimetic bispecific antibody (BsAb) for hemophilia A (HA), engineered from emicizumab. It is designed to achieve non-hemophiliac levels of plasma coagulation potential and is currently under clinical development. In
Kazuki Yamaguchi, Kenta Haraya, Hikaru Koga, Kei Nishimura, Keito Inaba, Masaru Muraoka, Atsushi Muto, Takehisa Kitazawa   +7 more
doaj   +1 more source

Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary

Therapeutic Advances in Hematology
Background: Systematically documented data on real-world use of emicizumab, a bispecific antibody factor (F)VIII mimetic, are still lacking in people with severe haemophilia A (PwSHA).
Carmen Escuriola Ettingshausen, Wolfgang Eberl, Hermann Eichler, Ronald Fischer, Christina Hart, Katharina Holstein, Ralf Knöfler, Jürgen Kreutz, Caspar David Kühnöl, Wolfgang A. Miesbach, Christian Pfrepper, Andreas Rösch, Ulrich J. Sachs, Karolin Trautmann-Grill, Wolfgang Mondorf   +14 more
doaj   +1 more source

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3

Haemophilia, EarlyView.
ABSTRACT Introduction Tissue factor pathway inhibitor (TFPI), a key regulator of tissue factor‐initiated coagulation through FXa‐dependent inhibition of the tissue factor‐FVIIa complex, has emerged as a promising target for restoring thrombin generation.
Mankai Ju, Feng Xue, Wei Sun, Fang Li, Ting Xu, Renchi Yang   +5 more
wiley   +1 more source

Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis [PDF]

Emicizumab is approved for prophylaxis of patients with hemophilia A (HA). Despite its efficacy in reducing bleeding, a few patients on emicizumab still experience hemarthrosis, but no tool is yet available to identify those at higher risk of spontaneous
Palla, Roberta, Gualtierotti, Roberta, Valsecchi, Carla, Scalambrino, Erica, Novembrino, Cristina, Begnozzi, Valentina, Hassan, Shermarke, Clerici, Marigrazia, Peyvandi, Flora, Arcudi, Sara, Boccalandro, Elena Anna   +10 more
core   +1 more source

Italian Patients Journey for Gene Therapy in Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno, Gaia Spadarella, Alessandra Borchiellini, Anna Borrelli, Andrea Buzzi, Giancarlo Castaman, Michele Cecchi, Raimondo De Cristofaro, Vincenzo La Mura, Angelo Lupi, Giuseppe Malcangi, Maria Elisa Mancuso, Maria Francesca Mansueto, Cristina Santoro, Rita Carlotta Santoro, Luigi Piero Solimeno, Annarita Tagliaferri, Ezio Zanon, Isabella Garagiola, Flora Peyvandi   +19 more
wiley   +1 more source

Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience

Annals of Hematology
Emicizumab is a FVIII mimetic antibody used in the treatment of inherited hemophilia A that could potentially be used in acquired hemophilia A (AHA) to achieve hemostasis and shorten hospital stay while reducing bypass therapies. We report on 12 cases of
Malcolm Su, Sean Yates, Melissa Sanchez, Yu-Min Shen   +3 more
doaj   +1 more source

Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates

Research and Practice in Thrombosis and Haemostasis
Background: Venous thromboembolic events have been reported in persons with hemophilia A who received emicizumab and activated prothrombin complex concentrate (APCC) concomitantly, but the relevant mechanism(s) remains unclear.
Yuto Nakajima, Mitsumasa Osuna, Kuniyoshi Mizumachi, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Keiji Nogami   +6 more
doaj   +1 more source

Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention

Research and Practice in Thrombosis and Haemostasis, 2019
Essentials Acquired hemophilia A is a rare bleeding disorder often accompanied by other comorbidities. We describe emicizumab use in acquired hemophilia A complicated by acute coronary syndrome.
Kathryn E. Dane, John P. Lindsley, Michael B. Streiff, Alison R. Moliterno, Mian K. Khalid, Satish Shanbhag   +5 more
doaj   +1 more source

Optimizing Emergency Department Care for People With Bleeding Disorders: A Scoping Review of Barriers and Interventions for Improvement

Haemophilia, EarlyView.
ABSTRACT Background Emergency department (ED) care is critical for managing acute bleeding events in people with bleeding disorders. Despite international guidelines recommending haemostatic treatment within 30–60 min, delays and deviations from best practices are common and associated with poorer outcomes.
Ling‐Yi Guo, Diane L. Lorenzetti, Natalia Rydz, Dawn Goodyear, Julia Hews‐Girard, Garrick Mok, Roy Khalife, Kelsey Uminski   +7 more
wiley   +1 more source

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source